Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T10:56:14.862Z Has data issue: false hasContentIssue false
  • English
  • Français

The Use of a Combination Antibiogram to Assist with the Selection of Appropriate Antimicrobial Therapy for Carbapenemase-Producing Enterobacteriaceae Infections

Published online by Cambridge University Press:  27 August 2015

Alice J. Hsu ,
Karen C. Carroll ,
Aaron M. Milstone ,
Edina Avdic ,
Sara E. Cosgrove ,
Mercedes Vilasoa  and
Pranita D. Tamma
Alice J. Hsu
Affiliation:
The Johns Hopkins Hospital, Department of Pharmacy, Baltimore, Maryland
Karen C. Carroll
Affiliation:
The Johns Hopkins Hospital, Department of Pathology and Medicine, Baltimore, Maryland
Aaron M. Milstone
Affiliation:
The Johns Hopkins University School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Diseases, Baltimore, Maryland
Edina Avdic
Affiliation:
The Johns Hopkins Hospital, Department of Pharmacy, Baltimore, Maryland
Sara E. Cosgrove
Affiliation:
The Johns Hopkins University School of Medicine, Department of Medicine, Division of Infectious Diseases, Baltimore, Maryland
Mercedes Vilasoa
Affiliation:
Stevenson University, Baltimore, Maryland.
Pranita D. Tamma*
Affiliation:
The Johns Hopkins University School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Diseases, Baltimore, Maryland
*
Address correspondence to Pranita D. Tamma, MD, MHS, The Johns Hopkins University School of Medicine, Department of Pediatrics, Division of Infectious Diseases, 200 North Wolfe Street, Suite 3155, Baltimore, Maryland 21287 (ptamma1@jhmi.edu).
Get access Rights & Permissions [Opens in a new window]

Abstract

Combination antibiograms can be used to evaluate organism cross-resistance among multiple antibiotics. As combination therapy is generally favored for the treatment of carbapenemase-producing Enterobacteriaceae (CPE), combination antibiograms provide valuable information about the combination of antibiotics that achieve the highest likelihood of adequate antibiotic coverage against CPE.

Infect. Control Hosp. Epidemiol. 2015;36(12):1458–1460

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 36 , Issue 12 , December 2015 , pp. 1458 - 1460
Copyright
© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Tzouvelekis, LS, Markogiannakis, A, Piperaki, E, Souli, M, Daikos, GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014;20:862–872.Google Scholar
2. Pogue, JM, Alaniz, C, Carver, PL, Pleva, M, Newton, D, DePestel, DD. Role of unit-specific combination antibiograms for improving the selection of appropriate empiric therapy for Gram-negative pneumonia. Infect Cont Hosp Epidemiol 2011;32:289–292.Google Scholar
3. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; approved standard. Twenty-fourth informational supplement. CLSI Document M100-S24. Wayne, PA: CLSI 2014.Google Scholar
4. Roberts, JA, Kirkpatrick, CM, Roberts, MS, Robertson, TA, Dalley, AJ, Lipman, J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009;64:142–150.Google Scholar
5. Daikos, GL, Panagiotakopoulou, A, Tzelepi, E, Loli, A, Tzouvelekis, LS, Miriagou, V. Activity of imipenem against VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model. Clin Micro Infect 2007;13:202–205.Google Scholar
6. Souli, M, Konstantinidou, E, Tzepi, I, et al. Efficacy of carbapenems against a metallo-beta-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model. J Antimicrob Chemother 2011;66:611–617.Google Scholar
7. Daikos, GL, Markogiannakis, A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011;17:1135–1141.CrossRefGoogle ScholarPubMed
8. Keel, RA, Sutherland, CA, Crandon, JL, Nicolau, DP. Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents 2011;37:184–185.Google Scholar
9. Yahav, D, Lador, A, Paul, M, Leibovici, L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66:1963–1971.CrossRefGoogle ScholarPubMed
10. Garonzik, SM, Li, J, Thamlikitkul, V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284–3294.Google Scholar